期刊
GENE
卷 745, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.gene.2020.144629
关键词
Sirtuin-3; Small-cell lung cancer; Mutant p53; Deacetylation; Apoptosis
资金
- National Natural Science Foundation of China, China [81501982, 81772794, 81672948, 81572927]
- Jilin Provincial Research Foundation for the Development of Science and Technology Projects [20170623021TC, 20160414005GH]
- Jilin Provincial Industrial Innovation Project [2018C052-7]
- Jilin University, China Bethune Plan B Projects [2015222, 2018A02]
- Jilin Province, China Health and Health Technology Innovation Project [2018 J061]
Small-cell lung cancer (SCLC) is the most invasive of all lung cancer subtypes, and is characterized by its rapid response to chemotherapy resistance. Overcoming chemotherapy resistance is therefore the key to treating SCLC. P53 is mutated in most SCLCs, which has an effect of enhancing chemotherapy resistance. Regulation of p53 proteins by a variety of post-translational modifications, such as acetylation, which affects their function. Acetylation and deacetylation of p53 may be potential targets for modulating chemosensitivity. Recent studies have shown that SIRT3 acts as a deacetylase that regulates acetylation of p53. However, whether SIRT3 can regulate the post-translational modification of mutant p53 has not been studied. In the present study, we found that SIRT3 can deacetylate mutant p53, thus reducing its expression, inducing apoptosis in SCLC cells, and increasing SCLC chemosensitivity. The relationship between SIRT3 and mutant p53 could be the basis of a new SCLC treatment approach.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据